Oculis (NASDAQ:OCS) Sees Strong Trading Volume Following Analyst Upgrade

Oculis Holding AG (NASDAQ:OCS) saw unusually-high trading volume on Friday after Robert W. Baird raised their price target on the stock from $37.00 to $41.00. Robert W. Baird currently has an outperform rating on the stock. Approximately 37,965 shares were traded during mid-day trading, a decline of 16% from the previous session’s volume of 45,132 shares.The stock last traded at $18.53 and had previously closed at $18.70.

Several other equities analysts also recently commented on OCS. Chardan Capital reiterated a “buy” rating and set a $28.00 price target on shares of Oculis in a report on Thursday. HC Wainwright lowered their price objective on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday.

Institutional Investors Weigh In On Oculis

A number of institutional investors have recently bought and sold shares of OCS. Bellevue Group AG acquired a new stake in Oculis during the fourth quarter worth $170,000. XTX Topco Ltd bought a new position in shares of Oculis during the fourth quarter valued at $225,000. Geode Capital Management LLC raised its holdings in shares of Oculis by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after buying an additional 1,800 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Oculis in the fourth quarter valued at about $389,000. Finally, Bank of America Corp DE raised its holdings in shares of Oculis by 58.2% in the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after buying an additional 10,667 shares during the last quarter. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis Stock Performance

The stock has a 50-day moving average of $20.92 and a 200 day moving average of $16.97. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.02 and a quick ratio of 4.02. The stock has a market capitalization of $760.26 million, a price-to-earnings ratio of -9.73 and a beta of 0.02.

Oculis (NASDAQ:OCS) last posted its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.28). Oculis had a negative return on equity of 71.31% and a negative net margin of 8,043.28%. On average, analysts expect that Oculis Holding AG will post -2.09 EPS for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.